PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

February 5, 2020 | Nightly News Rebroadcast

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded February 5, 2021

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded February 5, 2021

Show Me

Bannon’s War Room | Evening Edition | Recorded February 5, 2021

Show Me

February 4, 2020 | Nightly News Rebroadcast

Show Me

Why Texans Want to Leave the Union—Interview With Daniel Miller

Show Me

Mike Pence Joins Think Tank to Help ‘Lead the Conservative Movement Into the Future’

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded February 4, 2021

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded February 4, 2021

Show Me

Bannon’s War Room | Evening Edition | Recorded February 4, 2021

Show Me

February 3, 2020 | Nightly News Rebroadcast

Show Me

February 2, 2020 | Nightly News Rebroadcast

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded February 3, 2021

Show Me

LAA’s Braynard Calls on Stark County, OH to Reject ‘Black Box’ Voting Equipment Contract

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded February 3, 2021

Show Me

Bannon’s War Room | Evening Edition | Recorded February 3, 2021

Show Me

A Note To Readers About This Week

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded February 2, 2021

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded February 2, 2021

Show Me

Bannon’s War Room | Evening Edition | Recorded February 2, 2021

Show Me

Former CBP Commissioner: Biden’s Border Strategy Is ‘Release, Protect, Reward’

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded February 1, 2021

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded February 1, 2021

Show Me

Bannon’s War Room | Evening Edition | Recorded February 1, 2021

Show Me

February 1, 2021 | Nightly News Rebroadcast

Show Me

Bannon’s War Room
Saturday Edition Hour 1
Recorded January 30, 2021

Show Me

Bannon’s War Room
Saturday Edition Hour 2
Recorded January 30, 2021

Show Me

January 30, 2021
The Nation Speaks

Show Me

Twitter, Establishment Democrats’ Favorite Chat App, Can Be A Pedophile’s Best Friend

Show Me

January 29, 2020
Nightly News Rebroadcast

Show Me

LAA’s Braynard Discusses H.R.1 on OAN

Show Me

LAA ED Braynard Calls on DOJ, FBI To Drop Charges Against Non-Violent Capitol Protestors

Show Me

Bannon’s War Room
Morning Edition Hour 1
Recorded January 29, 2021

Show Me

Bannon’s War Room
Morning Edition Hour 2
Recorded January 29, 2021

Show Me

Bannon’s War Room
Evening Edition
Recorded January 29, 2021

Show Me

January 28, 2020
Nightly News Rebroadcast

Show Me

Bannon’s War Room
Morning Edition Hour 1
Recorded January 28, 2021

Show Me

VIDEO: The Reddit Revolution, GameStop and Melvin Capital

Show Me

Bannon’s War Room
Morning Edition Hour 2
Recorded January 28, 2021

Show Me

Bannon’s War Room
Evening Edition
Recorded January 28, 2021

Show Me